SPY435.00-7.64 -1.73%
DIA344.10-4.51 -1.29%
IXIC14,615.70-354.27 -2.37%

Keybanc Maintains Overweight on Quest Diagnostics, Raises Price Target to $168

Keybanc analyst Donald Hooker maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $144 to $168.

Benzinga · 09/01/2021 04:34
Keybanc analyst Donald Hooker maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $144 to $168.